Whatever the reasons behing the scenes if ICG had given a director of only 8 weeks standing 20mn shares at 5.4c I would have sold out and taken what profit remains off the table and I believe I would not have been alone.
The orginal idea was at 80% of VWAP in the 5 days preceding the issue.
To ask the board to throw this out the window and issue shares at a 60%+ discount to the VWAP of the previous 5 days (from 6th Feb) is outrageous imo.
The board were absolutely right to deny this extremely greedy request.
I also concur with those of the viewpoint that the ANN of 8th Feb reads very positively on both the outcome of upcoming assays and the board's attitude towards all shareholders - not just a select few.
I have been an active investor in ASX resource stocks since 2005 and an occasional investor in the sector since the 1980s.
I cannot recall ever seeing an ANN like this before relating to a resolution passed at an AGM the day before.
All credit to the board of directors for their decision and manner of communicating it to the market.
EB
- Forums
- ASX - By Stock
- ICG
- resignation of chair
resignation of chair, page-14
-
-
- There are more pages in this discussion • 71 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add ICG (ASX) to my watchlist
(20min delay)
|
|||||
Last
0.6¢ |
Change
0.000(0.00%) |
Mkt cap ! $6.160M |
Open | High | Low | Value | Volume |
0.6¢ | 0.6¢ | 0.6¢ | $2.4K | 400K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
5 | 2106494 | 0.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.6¢ | 2149226 | 7 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
5 | 2106494 | 0.005 |
8 | 2930194 | 0.004 |
13 | 19206780 | 0.003 |
4 | 4399980 | 0.002 |
3 | 6199950 | 0.001 |
Price($) | Vol. | No. |
---|---|---|
0.006 | 2149226 | 7 |
0.007 | 1447760 | 5 |
0.008 | 1950160 | 4 |
0.009 | 1033282 | 3 |
0.011 | 350000 | 1 |
Last trade - 10.04am 12/11/2024 (20 minute delay) ? |
Featured News
ICG (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Michael Thurn, CEO & MD
Michael Thurn
CEO & MD
Previous Video
Next Video
SPONSORED BY The Market Online